Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10294910" target="_blank" >RIV/00216208:11110/15:10294910 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/15:10294910

Result on the web

<a href="http://dx.doi.org/10.1016/j.clgc.2014.07.007" target="_blank" >http://dx.doi.org/10.1016/j.clgc.2014.07.007</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clgc.2014.07.007" target="_blank" >10.1016/j.clgc.2014.07.007</a>

Result language

angličtina

Original language name

Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study

Original language description

This large, prospective, noninterventional study assessed the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma (RCC) in a clinical practice setting. Sorafenib was generally well tolerated, with no unexpected adverse eventsobserved, and provided clinical benefit in this diverse patient population. Background: Patients with advanced renal cell carcinoma in routine clinical practice can differ considerably from those in phase III studies. Patients and Methods: PREDICT (Patient characteristics in REnal cell carcinoma and Daily practICe Treatment with sorafenib) was a prospective, noninterventional study of open-label sorafenib for the treatment of advanced RCC conducted in 18 countries. Patient characteristics, therapy duration, tumor status, and tolerability were assessed at baseline and during routine follow-up. Results: Overall, 2599 patients were evaluable for safety and 2311 for efficacy. The diverse population included patients with brain metastases (5

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Clinical Genitourinary Cancer

ISSN

1558-7673

e-ISSN

—

Volume of the periodical

13

Issue of the periodical within the volume

2

Country of publishing house

US - UNITED STATES

Number of pages

9

Pages from-to

156-164

UT code for WoS article

000351333100008

EID of the result in the Scopus database

2-s2.0-84924534433